Succinic Acid

Succinic Acid

SCHEMBL507209

CN(c1ccc2ccccc2c1)c1c(Cl)ccc2c1CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C known ✓ P28335 3/20 0.37
HTR2A known ✓ P28223 1/20 0.37
SLC6A4 known ✓ P31645 2/20 0.34
SLC6A2 known ✓ P23975 1/20 0.33
HTR2B P41595 7/20 0.39
MLNR O43193 1/20 0.37
CYP3A4 P08684 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
DOT1L Q8TEK3 1/20 0.34
KCNH2 Q12809 1/20 0.34
ACHE P22303 1/20 0.33
CYP1A2 P05177 1/20 0.33
S1PR5 Q9H228 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL506561 0.85 HTR2B (0.34) HTR2BHTR2CHTR2ARXRARXRB
Succinic Acid SCHEMBL507817 0.82 SLC6A9 (0.39) HTR2BHTR2CHTR2A
Succinic Acid SCHEMBL506423 0.79 DAGLA (0.39) HTR2BHTR2CHTR2ACYP3A4KCNH2
Succinic Acid SCHEMBL506535 0.78 HTR2B (0.36) HTR2BHTR2CHTR2ACYP3A4RXRA
Succinic Acid SCHEMBL507602 0.78 HTR2C (0.42) HTR2BHTR2CHTR2ARXRARXRB
Succinic Acid SCHEMBL507771 0.77 HTR2B (0.40) HTR2BHTR2CHTR2A
Succinic Acid SCHEMBL506941 0.77 RXRA (0.37) HTR2BHTR2CHTR2ACYP3A4RXRA
Succinic Acid SCHEMBL16456525 0.76 LTA4H (0.42) HTR2BHTR2CHTR2A
Succinic Acid SCHEMBL2369375 0.76 HTR2B (0.33) HTR2BHTR2CHTR2ARXRARXRB
Succinic Acid SCHEMBL508021 0.75 LTC4S (0.34) HTR2BHTR2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 HTR2C 1/4885HTR2A 4/4885SLC6A4 99/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A HTR2C 1/4885HTR2A 4/4885SLC6A4 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.